摘要
背景:在过去的几十年中,头颈部鳞状细胞癌(HNSCC)的生存率没有变化,五年的生存率只有50%。因此,迫切需要新的分子靶点的识别和新的治疗策略的开发。肿瘤-睾丸抗原(CTAs)在多种肿瘤中表达,但在正常健康组织中很少表达。因此,它们是免疫治疗方法的理想靶点,也是癌症诊断和预后的独特标志。目的:探讨肿瘤/睾丸抗原(CTA)在HNSCC组织中的表达规律,并与临床病理预后因素进行相关性分析。方法:应用CTA数据库中所有CTA基因进行AN筛查,用RT-PCR方法检测89例HNSCC和20例正常黏膜组织中8种CTA基因(ARMC 3、DDX 53、FTHL 17、GAGE 1、MAGEA 11、SYCE 1、TCP 11和XAGE 1)的表达。结果:GAGE 1(48.3%)、XAGE 1(40.4%)和MAGEA 11(19.1%)在HNSCC中有较高的特异性表达,其中68.5%的HNSCC中至少有1种抗原表达。此外,GAGE 1和XAGE 1基因的阳性表达与淋巴结转移密切相关(p=0.038和p=0.023),多因素分析显示男性性别(p=0.032)、晚期临床分期(p=0.018)和GAGE 1阳性率(p=0.010)是影响整体生存的独立预后因素。结论:GAGE 1和XAGE 1的表达可作为HNSCC的预后指标。
关键词: 头颈部鳞状细胞癌,癌/睾丸抗原,mRNA表达,预后指标,GAGE 1,XAGE 1。
Current Molecular Medicine
Title:Expression and Prognostic Relevance of GAGE1 and XAGE1 Cancer/Testis Antigens in Head and Neck Squamous Cell Carcinoma
Volume: 17 Issue: 10
关键词: 头颈部鳞状细胞癌,癌/睾丸抗原,mRNA表达,预后指标,GAGE 1,XAGE 1。
摘要: Background: In the last decades, survival rates in head and neck squamous cell carcinoma (HNSCC) have not changed, with a five-year survival of only 50%. Thus, there is a great need for the identification of new molecular targets and development of novel therapeutic strategies. Cancer-testis antigens (CTAs) are expressed in various types of tumor but rarely in healthy normal tissues. Therefore, they appear as ideal targets for immunotherapy approaches, as well as, unique markers for cancer diagnosis/prognosis.
Objective: This study evaluated the expression pattern of cancer/testis antigens (CTA) in HNSCC samples and correlated the expression data with the clinicopathological prognostic variables.
Methods: An in silico screening was performed using all CTA genes cataloged on the CTDatabase and the expression of the eight CTA genes (ARMC3, DDX53, FTHL17, GAGE1, MAGEA11, SYCE1, TCP11, and XAGE1) was examined in 89 HNSCC and 20 normal mucosa samples using RT-PCR analysis.
Results: GAGE1 (48.3%), XAGE1 (40.4%) and MAGEA11 (19.1%) were frequently and specifically expressed in HNSCC samples and 68.5% of the cases expressed at least one of these antigens. Moreover, GAGE1 and XAGE1 mRNA positivity was significantly associated with the presence of metastasis in the lymph nodes (p=0.038 and p=0.023, respectively) and, by multivariate analysis, male gender (p=0.032), advanced clinical stage (p=0.018) and mRNA positivity for GAGE1 (p=0.010) were independent prognostic factors for overall survival.
Conclusion: These findings suggest GAGE1 and XAGE1 expressions to be useful as prognostic markers for HNSCC.
Export Options
About this article
Cite this article as:
Expression and Prognostic Relevance of GAGE1 and XAGE1 Cancer/Testis Antigens in Head and Neck Squamous Cell Carcinoma, Current Molecular Medicine 2017; 17 (10) . https://dx.doi.org/10.2174/1566524018666180322162145
DOI https://dx.doi.org/10.2174/1566524018666180322162145 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers
Recent Patents on Anti-Cancer Drug Discovery Viral-Mediated Gene Transfer for Cancer Treatment
Current Pharmaceutical Biotechnology Effective Treatment of Human Lung Cancer by Targeting Tissue Factor with a Factor VII-Targeted Photodynamic Therapy
Current Cancer Drug Targets Can PET Imaging Facilitate Optimization of Cancer Therapies?
Current Pharmaceutical Design Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases
Current Pharmaceutical Design Bone Invasive Properties of Oral Squamous Cell Carcinoma and its Interactions with Alveolar Bone Cells: An In Vitro Study
Current Cancer Drug Targets Activities of Venom Proteins and Peptides with Possible Therapeutic Applications from Bees and WASPS
Protein & Peptide Letters Long Non-Coding RNAs As Epigenetic Regulators in Cancer
Current Pharmaceutical Design Adenoviral Vector-Mediated Gene Transfer for Human Gene Therapy
Current Gene Therapy Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Radiolabelled Peptides and Monoclonal Antibodies for Therapy Decision Making in Inflammatory Diseases
Current Pharmaceutical Design Advances in the Researches on the Biological Activities and Inhibitors of Phosphatidylinositol 3-kinase
Anti-Cancer Agents in Medicinal Chemistry The Structure and Function of Histone Deacetylases: The Target for Anti-cancer Therapy
Current Medicinal Chemistry Targeting Cancer Stem Cell Lines as a New Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery Diagnostic and Therapeutic Applications of Recombinant Antibodies:Targeting the Extra-Domain B of Fibronectin, A Marker of Tumor Angiogenesis
Current Pharmaceutical Design Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents
Current Drug Targets Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Detection of Residual/Recurrent Cervical Disease after Successful LEEP Conization: the Possible Role of mRNA-HPV Test
Current Pharmaceutical Design Chronobiology of the Neuroimmunoendocrine System and Aging
Current Pharmaceutical Design